Dymicron Announces First Patient Enrolled in Triadyme-C IDE Clinical Trial (opens in new tab)
Dymicron® announced the successful enrollment and treatment of the first patient in its Triadyme®-C Investigational Device Exemption (IDE) clinical trial.
Read the original article